Form 4: Dermata Therapeutics Director Acquires Stock Options

A Dermata Therapeutics director, Mary Fisher, acquired 5,000 stock options on January 13, 2025, at an exercise price of $1.38.

Summary

• Mary Fisher, a director at Dermata Therapeutics, acquired 5,000 stock options on January 13, 2025.
• The exercise price for these options is $1.38 per share.
• The options vest in twelve equal monthly installments, starting one month after the grant date, contingent on continuous service.
• The options expire on January 12, 2035.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction, not particularly positive or negative, but indicates a director's continued involvement with the company.

Positives

• The acquisition of stock options by a director may indicate confidence in the company's future performance.

Industry Context

This is a standard transaction for a director of a public company, often used as part of compensation and incentive programs.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of monthly installments over a year is also a typical arrangement to incentivize long-term commitment.
• The exercise price of $1.38 is specific to Dermata Therapeutics and would need to be compared to the current market price of the stock to assess its value.

Stakeholder Impact

• The stock option grant may be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, Dermata Therapeutics, director, insider trading, equity, DRMA, vesting